If you run a biotech or pharmaceutical company — even a small one, even one that isn't profitable yet — the federal R&D tax credit is probably the single most valuable tax benefit available to you. And most founders and CFOs either don't know how large it can be or are leaving money on the table because they're not documenting it correctly.
This guide covers exactly what qualifies, how the credit is calculated, what biotech-specific pitfalls to avoid and how much your company is likely owed.
The federal R&D tax credit under IRC Section 41 was designed with exactly your industry in mind. Drug discovery, clinical formulation, biologics development, diagnostic tool creation, device prototyping — these activities sit squarely in the IRS's definition of qualified research.
What makes biotech uniquely positioned is the scale of qualifying expenses. A software company might have $300k in developer salaries that qualify. A biotech company might have $2M in researcher wages, $500k in lab supplies and reagents and $400k in contracted research at a CRO — all potentially qualifying. The credit percentages are the same but the base is far larger.
Every activity must meet all four criteria under IRC Section 41(d) to count as qualified research:
Biotech and pharma companies almost universally pass all four tests. The harder question is documentation — which we cover later.
Any W-2 employee who spends time on qualified research activities contributes their wages to your QRE base. This includes:
You don't need to count their entire salary — only the percentage of time spent on qualifying activities. A PI who spends 80% of their time on qualifying research contributes 80% of their wages.
Supplies consumed in the research process qualify. This is often a significant category for biotech companies:
Important: Equipment and capital assets do not qualify as supplies. The cost of a centrifuge goes on your balance sheet, not your QRE. But the reagents used in that centrifuge do.
If you outsource research to a CRO, academic lab or independent contractor, 65% of what you pay them counts toward your QREs — provided you own the research results and bear the financial risk if it fails.
Your contract must establish that your company retains rights to the research results. If the CRO owns the IP, you cannot claim the credit. Review your contracts with your tax advisor before claiming CRO expenses.
| Activity / Expense | Qualifies? | Why |
|---|---|---|
| Pre-clinical drug discovery | Yes | Core qualifying research |
| Phase I / II clinical trials | Yes | Uncertainty still exists; you're testing hypotheses |
| Phase III clinical trials | Partial | Some activities qualify; post-approval studies typically don't |
| Routine quality control | No | Not aimed at eliminating technical uncertainty |
| Funded research (grants) | No | Must bear financial risk; funded research is excluded |
| Foreign research expenses | No | Credit applies only to US-based research |
| Social science or market research | No | Must be technological in nature |
| Capital equipment purchases | No | Supplies only; equipment is depreciated separately |
| FDA regulatory submissions | Partial | Research-generating activities qualify; pure filing does not |
This gives you 20% of the increase in QREs above a base amount. The base amount is calculated from your historical R&D spending as a percentage of gross receipts — complex but often the larger credit for established companies.
14% of QREs that exceed 50% of your average QREs over the prior 3 years. If you have no prior-year QREs, the rate is 6% of current-year QREs. This is simpler to calculate and the method most small biotech companies use.
A 3-year-old biotech company has:
Most early-stage biotech companies aren't profitable. Does that mean the R&D credit is useless to them? No. Under the PATH Act (expanded by the Inflation Reduction Act), startups with gross receipts under $5M and fewer than 5 years of revenue can apply up to $500,000 per year against employer-side payroll taxes instead of income tax.
You elect this on your business tax return (Form 6765, Section D). The credit then flows to Form 8974, which you attach to your quarterly payroll tax returns (Form 941). Most payroll processors can handle this once your accountant sets it up.
If you're audited, documentation is everything. Biotech companies have an advantage: most already keep detailed research records. The challenge is mapping those records to the IRS's framework.
Practically: if your scientists keep lab notebooks and you have project management records (Notion, Jira, lab management software), you're in better shape than you think. A qualified R&D tax specialist can help you organize existing records into a defensible study.
Partially. Activities in Phase III that still involve eliminating technical uncertainty typically qualify. Routine data collection and post-approval studies generally don't. This needs to be analyzed activity-by-activity.
Only for the research funded by the grant. If you have any self-funded research activities, those still qualify.
California (15% for small businesses), Massachusetts (10%), Maryland (10%), New Jersey (10%) and others stack on top of the federal credit.
No. The credit applies to the research activity, not the outcome. Failed experiments are still qualified research.
Take our free 90-second eligibility check. No email required. Find out if it's worth talking to a specialist.
Check My Eligibility →